Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index

https://doi.org/10.1016/j.jhep.2005.02.025Get rights and content

Background/Aims

To examine if serum fibrosis biomarkers could accurately identify the stage of liver disease amongst hepatitis C (HCV) and HIV co-infected patients.

Methods

One hundred and thirty seven HIV/HCV co-infected persons were randomly selected from the Johns Hopkins HIV Clinic cohort. Ninety five had complete testing for fibrosis markers in sera collected at the time of liver biopsy. Biopsies were scored according to Ishak modified histological activity index (F0 no fibrosis to F6 cirrhosis). Fibrosis was evaluated against alanine aminotransferase (ALT), aspartate aminotransferase (AST), AST to platelet ratio (APRI), albumin, total bilirubin, hyaluronic acid (HA) and YKL-40.

Results

Sixty nine (73%) had no or minimal portal fibrosis (F0-2) and were compared with remaining subjects (F3-6). Fibrosis scores ≥F3 were found 27 times more often in persons with HA levels >86 ng/ml and 5.5 times more often in persons with HA levels 41–86 ng/ml. Less substantial associations were detected with levels of albumin <3.5 g/dl (OR 4.85) and AST >60 iu (OR 5.91). All 35 subjects who had favorable results of HA, albumin, and AST had minimal fibrosis (F0-2).

Conclusions

Amongst HIV/HCV co-infected patients, serum testing for HA, albumin, and AST (SHASTA Index) was able to accurately stage mild and advanced fibrosis.

Introduction

Chronic hepatitis C is characterized by slowly progressive hepatic fibrosis. The fibrogenic stimulus transforms the quiescent hepatic stellate cells (HSCs) into myofibroblast-like cells which degrade normal extracellular matrix (ECM) with accumulation of collagen [1]. Collagen accumulation results in architectural distortion with portal fibrosis leading to bridging fibrosis and eventually cirrhosis. The currently accepted gold standard in fibrosis determination is liver biopsy [2], [3]. Although widely performed and accepted in diagnosing hepatic fibrosis, liver biopsy has many inherent shortcomings.

Percutaneous liver biopsy is invasive with associated morbidity. Approximately 1–3% of patients require hospital admission following biopsy for an associated complication [4]. Furthermore, even with experienced physicians performing the biopsy and expert pathologists interpreting them, our so called gold standard has up to a 20% error rate in staging disease predominantly related to sampling error [5], [6].

Ideally serum markers of fibrosis could either replace the need for liver biopsy or identify those patients with more advanced liver disease who may benefit from a liver biopsy. Features essential of such proposed markers include hepatic specificity, ease of determination and ability to discriminate between degrees of fibrosis. Ultimately serum markers may even have the ability to determine response to various therapies and evaluate disease progression [1].

No single marker fulfills all of the proposed criteria to merit routine clinical use. A combination of markers including those that reflect alterations in hepatic synthetic function and markers of extracellular matrix turnover are emerging as useful diagnostic tests for differentiating early from advanced fibrosis [7], [8].

Hepatitis C and HIV co-infection is estimated to affect 200,000 people in the US alone [9], [10]. Co-infection is associated with more rapid progression of fibrosis, liver failure and hepatocellular carcinoma [11], [12], [13], [14], [15]. Consequently, there is an urgent need for reliable markers of fibrosis progression in this patient group. In this study we report the sensitivity, specificity and predictive value of existing putative fibrosis markers in a cohort of HIV/HCV co-infected persons receiving treatment in an urban HIV clinic.

Section snippets

Study subjects

The population for this study derives from HIV/HCV co-infected members of the Johns Hopkins University (JHU) HIV clinic cohort in Baltimore, MD. To obtain an unbiased estimate of the prevalence and severity of liver disease among HIV–HCV co-infected persons treated with anti-retroviral therapy (ART), 137 subjects were randomly selected from a group of 630 HIV–HCV co-infected persons who had received ART for two or more years and had not yet received treatment for HCV infection [16]. Of the 137

Results

Among the 95 subjects, the median age was 45, 63% were male and 94% were African–American (Table 1). The median CD4 cell count was 340 (interquartile range [IQR], 155–523) and the median HIV RNA level was 235 copies/ml (IOR, 31–19,238). The median HCV RNA level was 3,740,000 IU/ml (IQR, 1,290,000–5,870,000). No patients were positive for HBV DNA.

Discussion

Liver biopsy is the predominant diagnostic test upon which determination of prognosis and indeed the need for antiviral therapy is made in patients with chronic hepatitis C although its performance in accurately staging liver disease has recently come into focus. A recent study on virtual liver biopsy has suggested that liver biopsies need to be 25 mm long and non-fragmented to accurately stage disease in 80% of patients [20]. However, that goal is rarely achieved in clinical practice (<25% even

Acknowledgements

Financial support for this study came from DA-11602, DA-16065 and DA-13806 from the National Institute on Injection Drug Abuse, grant HS 07-809 from the Agency for Health Care Policy and Research and MO1-RR00052.

References (33)

  • W.M. Rosenberg et al.

    Serum markers detect the presence of liver fibrosis: a cohort study

    Gastroenterology

    (2004)
  • S.L. Friedman

    Liver fibrosis–from bench to bedside

    J Hepatol

    (2003)
  • D.B. Strader et al.

    Diagnosis, management, and treatment of hepatitis C

    Hepatology

    (2004)
  • H. Orlent et al.

    Hepatitis C 2002 guidelines: summary and annotations

    Scand J Gastroenterol Suppl

    (2003)
  • A.A. Bravo et al.

    Liver biopsy

    N Engl J Med

    (2001)
  • D. Thabut et al.

    Noninvasive prediction of fibrosis in patients with chronic hepatitis C

    Hepatology

    (2003)
  • Cited by (0)

    View full text